Company profile · Biotech & medical
和迅生命科學股份有限公司 · 6986
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
HeXun Biosciences develops and sells new drugs, focusing on the development of allogeneic umbilical cord mesenchymal stem cell new drugs.[1]
The company provides contract development and manufacturing services, testing services, aseptic filling services, and laboratory construction and quality document consulting services.[2]
HeXun Biosciences is based in Taoyuan, Taiwan.[1]
After subscribing, check your inbox (and spam folder) and confirm your subscription. We do this to protect you from spammers.
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$11m | -59.8% | -36.4% |
2024-11 to 2026-10, monthly revenue.
| Last 19 trading days | Net |
|---|---|
| 2026-10-15 to 2026-11-13 | +NT$1m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
| Full English name | HeXun Biosciences Co., Ltd. |
|---|---|
| Chinese name | 和迅生命科學股份有限公司 |
| Stock code | 6986 (TPEx) |
| Industry | Biotech & medical |
| Founded | 12 Jun 2019 |
| Listed | 26 Jun 2026 |
| Paid-in capital | NT$521m |
| Chairman | 黃濟鴻 |
| President | 黃濟鴻 |
| Headquarters | 6 F., No. 1490, Chunri Rd., Taoyuan Dist. Taoyuan City 33022, Taiwan (R.O.C.) |
| Website | https://www.hexunbio.com/ |
| Official business description | 新藥開發及銷售 · 委託開發暨製造(CMO/CDMO) · 檢測服務 |
Facts from MOPS company basic information, retrieved 12 Nov 2026. The official business description is the company's own entry and can be out of date.
After subscribing, check your inbox (and spam folder) and confirm your subscription. We do this to protect you from spammers.
Generated 2026-11-15 00:39.